

Charles Khouri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6428328/charles-khouri-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

365
citations

11
h-index

18
g-index

49
ext. papers

589
ext. citations

7
avg, IF

4.15
L-index

#	Paper	IF	Citations
40	The French health pass holds lessons for mandatory COVID-19 vaccination.. <i>Nature Medicine</i> , 2022 ,	50.5	7
39	Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action.. <i>British Journal of Clinical Pharmacology</i> , 2022 ,	3.8	0
38	Triptans and SCAD: An Analysis From the WHO Pharmacovigilance Database. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2129-2130	15.1	
37	Adenovirus COVID-19 Vaccines and Guillain-Barré Syndrome with Facial Paralysis. <i>Annals of Neurology</i> , 2021 , 91, 162	9.4	4
36	Adverse event reporting and Bell's palsy risk after COVID-19 vaccination. <i>Lancet Infectious Diseases</i> , 2021 , 21, 1490-1491	25.5	0
35	Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances. <i>Frontiers in Pharmacology</i> , 2021 , 12, 668765	5.6	4
34	Skin necrosis and calcifications after extravasation of vancomycin: a localised form of calciphylaxis?. <i>Journal of Wound Care</i> , 2021 , 30, 390-393	2.2	2
33	Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
32	Gout and Levodopa: An unknown adverse effect?. <i>Fundamental and Clinical Pharmacology</i> , 2021 ,	3.1	1
31	Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. <i>Journal of Clinical Epidemiology</i> , 2021 , 134, 14-21	5.7	17
30	Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 229-232	4.5	0
29	Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. <i>Annals of Internal Medicine</i> , 2021 , 174, 878-880	8	8
28	Impact of Bariatric Surgery on Medication Efficacy: an Analysis of World Health Organization Pharmacovigilance Data. <i>Obesity Surgery</i> , 2021 , 31, 2823-2830	3.7	0
27	Caution in Interpreting Facial Paralysis Data to Understand COVID-19 Vaccination Risks-Reply. <i>JAMA Internal Medicine</i> , 2021 , 181, 1420-1421	11.5	
26	Intermittent hypoxia-related alterations in vascular structure and function: a systematic review and meta-analysis of rodent data. <i>European Respiratory Journal</i> , 2021 ,	13.6	2
25	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1306-1315	4.7	0
24	Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. <i>JAMA Internal Medicine</i> , 2021 , 181, 1243-1245	11.5	35

23	Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	2
22	High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2021 , 138, 73-79	5.7	3
21	A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. <i>Journal of Clinical Epidemiology</i> , 2021 , 139, 191-198	5.7	3
20	Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2217-2222	3.8	7
19	Treatment efficacy in secondary Raynaud's phenomenon: Authors' reply. <i>Lancet Rheumatology</i> , 2020 , 2, e132-e133	14.2	
18	Impact of global warming on Raynaud's phenomenon: a modelling study. <i>F1000Research</i> , 2020 , 9, 829	3.6	0
17	Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 2406-2408.e1	5.4	3
16	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	21
15	French translation and linguistic validation of the Raynaud's condition score. <i>Therapie</i> , 2019 , 74, 627-631	3.8	2
14	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. <i>Lancet Rheumatology</i> , 2019 , 1, e237-e246	14.2	11
13	Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase. <i>Dermatologic Surgery</i> , 2019 , 45, 1517-1528	1.7	1
12	Severe central sleep apnoea associated with nalmefene: a case report. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1075-1076	3.8	4
11	SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1531-1534	6.7	62
10	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. <i>Chest</i> , 2018 , 154, 136-147	5.3	13
9	Proton pump inhibitors and Raynaud's phenomenon: is there a link?. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2443-2444	3.8	2
8	On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. <i>Annals of Internal Medicine</i> , 2018 , 169, 694-703	8	17
7	Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1427-1428	2.6	2
6	Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension. <i>Trends in Pharmacological Sciences</i> , 2017 , 38, 512-523	13.2	31

5	Fluoxetine and Raynaud's phenomenon: friend or foe?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2307-2309	3.8	5
4	Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: An effect size meta-analysis. <i>Wound Repair and Regeneration</i> , 2017 , 25, 883-891	3.6	26
3	Drug-induced Raynaud's phenomenon: beyond β -adrenoceptor blockers. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 6-16	3.8	35
2	Peripheral vasoconstriction induced by β -adrenoceptor blockers: a systematic review and a network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 549-60	3.8	11
1	Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014 , 38, e103-5	2.4	11